Literature DB >> 29402145

High NUP43 expression might independently predict poor overall survival in luminal A and in HER2+ breast cancer.

Chao Tian1,2, Shijie Zhou1, Cheng Yi1.   

Abstract

AIM: To explore the independent prognostic value of NUP43 in terms of overall survival (OS) and the mechanisms of its dysregulation in breast cancer. PATIENTS &
METHODS: Bioinformatic analysis was performed by using data from The Cancer Genome Atlas-breast invasive carcinoma.
RESULTS: High NUP43 expression was an independent prognostic factor of poor OS in luminal A subtype (HR: 2.400; 95% CI: 1.070-5.379; p = 0.034) and in HER2+ subtype (HR: 10.578; 95% CI: 1.850-60.473; p = 0.008). NUP43 DNA amplification was associated with elevated NUP43 expression, while DNA deletion was associated with decreased NUP43 transcription.
CONCLUSION: NUP43 upregulation was related to DNA amplification and might independently predict poor OS in luminal A and in HER2+ breast tumors.

Entities:  

Keywords:  NUP43; breast cancer; luminal A; overall survival

Mesh:

Substances:

Year:  2018        PMID: 29402145     DOI: 10.2217/fon-2017-0690

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  10 in total

1.  PCMT1 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltrates in Breast Cancer.

Authors:  Jufang Guo; Xuelian Du; Chaolin Li
Journal:  Biomed Res Int       Date:  2022-04-30       Impact factor: 3.246

2.  Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer.

Authors:  Xueting Ren; Hanxiao Cui; Jianhua Wu; Ruina Zhou; Nan Wang; Dandan Liu; Xin Xie; Hao Zhang; Di Liu; Xiaobin Ma; Chengxue Dang; Huafeng Kang; Shuai Lin
Journal:  Cancer Med       Date:  2022-04-20       Impact factor: 4.711

3.  Long Non-Coding RNA NCK1-AS1 Serves an Oncogenic Role in Gastric Cancer by Regulating miR-137/NUP43 Axis.

Authors:  Wenxing Li; Jiming Duan; Wenbin Shi; Liqiang Lei; Pin Lv
Journal:  Onco Targets Ther       Date:  2020-10-06       Impact factor: 4.147

4.  Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer.

Authors:  Lijuan Lyu; Meng Wang; Yi Zheng; Tian Tian; Yujiao Deng; Peng Xu; Shuai Lin; Si Yang; Linghui Zhou; Qian Hao; Ying Wu; Zhijun Dai; Huafeng Kang
Journal:  Cancer Manag Res       Date:  2020-12-03       Impact factor: 3.989

Review 5.  Oncogenic potential of nucleoporins in non-hematological cancers: recent update beyond chromosome translocation and gene fusion.

Authors:  Adhiraj Roy; Gopeshwar Narayan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-25       Impact factor: 4.553

6.  Overexpression of TRMT12 may independently predict poor overall survival in patients with head and neck squamous cell carcinoma.

Authors:  Kai Wang; Mengmeng Zheng; Yuan Ren
Journal:  Onco Targets Ther       Date:  2019-09-05       Impact factor: 4.147

7.  Identification of a Novel Glycolysis-Related Gene Signature for Predicting Breast Cancer Survival.

Authors:  Dai Zhang; Yi Zheng; Si Yang; Yiche Li; Meng Wang; Jia Yao; Yujiao Deng; Na Li; Bajin Wei; Ying Wu; Yuyao Zhu; Hongtao Li; Zhijun Dai
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

8.  A Novel Glycolysis-Related Four-mRNA Signature for Predicting the Survival of Patients With Breast Cancer.

Authors:  Xiaolu Zhang; Jia Wang; Jing Zhuang; Cun Liu; Chundi Gao; Huayao Li; Xiaoran Ma; Jie Li; Changgang Sun
Journal:  Front Genet       Date:  2021-01-28       Impact factor: 4.599

9.  Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.

Authors:  Ricardo Noriega-Rivera; Mariela Rivera-Serrano; Robert J Rabelo-Fernandez; Josué Pérez-Santiago; Fatima Valiyeva; Pablo E Vivas-Mejía
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

10.  In silico development and validation of a novel glucose and lipid metabolism-related gene signature in gastric cancer.

Authors:  Yuan Yang; Zhaofeng Chen; Qinghong Guo; Yongning Zhou; Lingshan Zhou; Guozhi Wu; Xiaomei Ma; Ya Zheng; Min Liu; Yuping Wang; Rui Ji
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.